KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) EBT Margin (2016 - 2025)

Historic EBT Margin for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to 8.93%.

  • Fulgent Genetics' EBT Margin rose 169000.0% to 8.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.46%, marking a year-over-year increase of 526200.0%. This contributed to the annual value of 18.33% for FY2024, which is 418600.0% up from last year.
  • As of Q3 2025, Fulgent Genetics' EBT Margin stood at 8.93%, which was up 169000.0% from 26.31% recorded in Q2 2025.
  • Fulgent Genetics' EBT Margin's 5-year high stood at 74.34% during Q1 2021, with a 5-year trough of 205.94% in Q4 2023.
  • Over the past 5 years, Fulgent Genetics' median EBT Margin value was 10.56% (recorded in 2024), while the average stood at 4.28%.
  • As far as peak fluctuations go, Fulgent Genetics' EBT Margin plummeted by -1565100bps in 2023, and later soared by 1953800bps in 2024.
  • Quarter analysis of 5 years shows Fulgent Genetics' EBT Margin stood at 59.93% in 2021, then plummeted by -182bps to 49.42% in 2022, then tumbled by -317bps to 205.94% in 2023, then soared by 95bps to 10.56% in 2024, then increased by 15bps to 8.93% in 2025.
  • Its EBT Margin stands at 8.93% for Q3 2025, versus 26.31% for Q2 2025 and 15.96% for Q1 2025.